UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 2054
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|||
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (
N/A
(Former name, or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities Registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On November 9, 2022, Alpha Teknova, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022 (the “Press Release”). A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the Press Release, is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
99.1 |
|
Press Release issued by Alpha Teknova, Inc., dated November 9, 2022 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ALPHA TEKNOVA, INC. |
|
Date: November 9, 2022 |
By: |
/s/ Stephen Gunstream |
|
|
Stephen Gunstream |
|
|
President and Chief Executive Officer |
Exhibit 99.1
Teknova Reports Third Quarter 2022 Financial Results
Third quarter 2022 total revenue was $10.7 million, up 14% year-over-year
Company updates 2022 revenue outlook to $40-42 million
Cash position of $50 million supports path to profitability
HOLLISTER, Calif., November 9, 2022 – Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, research, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2022.
“Teknova delivered a solid third quarter revenue performance, driven by robust Lab Essentials growth and healthy demand across our broad customer base,” said Stephen Gunstream, President and CEO of Teknova. “Most recently, we entered the qualification phase of our new state-of-the-art production facility and announced an Early Access Program for the first novel products to emerge from our R&D pipeline. We are balancing selective strategic investments with prudent management of our capital to position Teknova for accelerated growth and remain on our path to profitability.”
Corporate and Financial Updates
1
Revenue for the Third Quarter and Year-to-Date 2022
|
|
For the Three Months Ended September 30, |
|
|
For the Nine Months Ended September 30, |
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Lab Essentials |
|
$ |
9,470 |
|
|
$ |
7,195 |
|
|
$ |
24,838 |
|
|
$ |
20,440 |
|
Clinical Solutions |
|
|
919 |
|
|
|
1,690 |
|
|
|
7,673 |
|
|
|
4,354 |
|
Sample Transport |
|
|
— |
|
|
|
73 |
|
|
|
6 |
|
|
|
1,035 |
|
Other |
|
|
303 |
|
|
|
434 |
|
|
|
1,012 |
|
|
|
954 |
|
Total revenue |
|
$ |
10,692 |
|
|
$ |
9,392 |
|
|
$ |
33,529 |
|
|
$ |
26,783 |
|
Third Quarter 2022 Financial Results
Total revenue for the third quarter 2022 was $10.7 million, up 14% compared to $9.4 million in the third quarter 2021.
Gross profit for the third quarter 2022 was $4.8 million, compared to $4.3 million in the third quarter 2021. Gross margin for the third quarter 2022 was 44.6% of revenue. This compares to gross margin of 45.4% in the third quarter 2021. The lower gross margin for the third quarter 2022 compared to the gross margin in the prior year primarily reflects additional headcount resulting in higher labor costs.
Operating expenses for the third quarter 2022 were $27.7 million compared to $8.2 million in the third quarter 2021. The increase was primarily related to a one-time, $16.6 million non-cash goodwill impairment charge in the quarter, coupled with additional headcount, stock-based compensation expense, and marketing costs.
Net loss for the third quarter 2022 was $22.5 million, or negative $0.80 per diluted share, compared to net loss of $3.3 million, or negative $0.12 per diluted share, for the third quarter 2021.
Cash used in operating activities for the third quarter 2022 was $8.3 million, compared to cash used in operating activities of $4.8 million for the third quarter 2021.
Adjusted EBITDA for the third quarter 2022 was negative $4.6 million, compared to negative $2.7 million for the third quarter 2021. Free Cash Flow was negative $14.9 million for the third quarter 2022, compared to negative $8.7 million for the third quarter 2021.
2022 Revenue Outlook
Teknova is updating its outlook for the fiscal year ending December 31, 2022, to total revenue of $40 million to $42 million, which assumes approximately 16% growth at the mid-point of guidance, excluding Sample Transport revenue earned in 2021. The Company expects an approximately 15% increase in Lab Essentials and at least a 25% increase in Clinical Solutions revenue to drive total revenue growth for the year. The Company does not anticipate any material revenue from Sample Transport in 2022.
2
Conference Call and Webcast
Teknova will host a webcast and conference call on Wednesday, November 9, 2022, beginning at 4:30 p.m. ET. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/rjjxxr67. To receive a PIN number for dial in, participants can register for the webcast via this link: https://register.vevent.com/register/BIc8c72fb8e9214c49b689933915e724ad. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Teknova
Teknova is expediting clinical breakthroughs in life sciences by providing custom products and reagents for drug therapies, novel vaccines, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products, including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high-quality, custom, made-to-order products with short turnaround times and at scale across all stages of development, including commercialization.
Non-GAAP Financial Measures
This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of its business and the effectiveness of its business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow.
Teknova defines Adjusted EBITDA as net loss adjusted for interest income (expense), net, benefit from income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance.
Teknova defines Free Cash Flow as cash used in operating activities less purchases of property, plant, and equipment.
Teknova presents Adjusted EBITDA and Free Cash Flow in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova's industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova's operating results because they exclude items that are not indicative of Teknova's core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial
3
performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.
A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, expected growth in Lab Essentials and Clinical Solutions, ongoing capacity expansion, new research and development products, prospects, including to achieve profitability, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, demand for Teknova’s products (including the delay or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s ability to expand its production capacity and commercial and R&D capabilities; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing and warehousing; inventory management; risks related to global economic and marketplace uncertainties related to the impact of the COVID-19 pandemic, including the impact of the pandemic on Teknova’s supply chain; reliance on a limited number of customers for a high percentage of Teknova’s revenue; potential acquisitions and integration of other companies and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by Teknova on its website or otherwise. Teknova does not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
4
Investor Contacts Media Contact
Matt Lowell Jenn Henry
Chief Financial Officer Senior Vice President, Marketing
matt.lowell@teknova.com jenn.henry@teknova.com
+1 831-637-1100 +1 831-313-1259
Sara Michelmore
MacDougall Advisors
smichelmore@macdougall.bio
+1 781-235-3060
5
ALPHA TEKNOVA, INC.
Condensed Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
|
|
For the Three Months Ended September 30, |
|
|
For the Nine Months Ended September 30, |
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Revenue |
|
$ |
10,692 |
|
|
$ |
9,392 |
|
|
$ |
33,529 |
|
|
$ |
26,783 |
|
Cost of sales |
|
|
5,922 |
|
|
|
5,129 |
|
|
|
18,163 |
|
|
|
14,141 |
|
Gross profit |
|
|
4,770 |
|
|
|
4,263 |
|
|
|
15,366 |
|
|
|
12,642 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
1,925 |
|
|
|
1,372 |
|
|
|
5,867 |
|
|
|
2,922 |
|
Sales and marketing |
|
|
2,397 |
|
|
|
885 |
|
|
|
6,592 |
|
|
|
2,494 |
|
General and administrative |
|
|
6,502 |
|
|
|
5,607 |
|
|
|
20,856 |
|
|
|
13,606 |
|
Amortization of intangible assets |
|
|
287 |
|
|
|
287 |
|
|
|
861 |
|
|
|
861 |
|
Goodwill impairment |
|
|
16,613 |
|
|
|
— |
|
|
|
16,613 |
|
|
|
— |
|
Total operating expenses |
|
|
27,724 |
|
|
|
8,151 |
|
|
|
50,789 |
|
|
|
19,883 |
|
Loss from operations |
|
|
(22,954 |
) |
|
|
(3,888 |
) |
|
|
(35,423 |
) |
|
|
(7,241 |
) |
Other income (expenses), net |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income (expense), net |
|
|
70 |
|
|
|
(255 |
) |
|
|
85 |
|
|
|
(553 |
) |
Other income (expense), net |
|
|
36 |
|
|
|
— |
|
|
|
36 |
|
|
|
(2 |
) |
Total other income (expenses), net |
|
|
106 |
|
|
|
(255 |
) |
|
|
121 |
|
|
|
(555 |
) |
Loss before income taxes |
|
|
(22,848 |
) |
|
|
(4,143 |
) |
|
|
(35,302 |
) |
|
|
(7,796 |
) |
Benefit from income taxes |
|
|
(374 |
) |
|
|
(892 |
) |
|
|
(1,128 |
) |
|
|
(1,640 |
) |
Net loss |
|
$ |
(22,474 |
) |
|
$ |
(3,251 |
) |
|
$ |
(34,174 |
) |
|
$ |
(6,156 |
) |
Net loss per share—basic and diluted |
|
$ |
(0.80 |
) |
|
$ |
(0.12 |
) |
|
$ |
(1.22 |
) |
|
$ |
(0.51 |
) |
Weighted average shares used in computing net loss per share—basic and diluted |
|
|
28,090,267 |
|
|
|
28,011,917 |
|
|
|
28,059,897 |
|
|
|
12,069,214 |
|
6
ALPHA TEKNOVA, INC.
Condensed Balance Sheets
(Unaudited)
(In thousands)
|
|
As of September 30, |
|
|
As of December 31, |
|
||
|
|
2022 |
|
|
2021 |
|
||
ASSETS |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
49,855 |
|
|
$ |
87,518 |
|
Accounts receivable, net |
|
|
5,581 |
|
|
|
4,666 |
|
Contract assets |
|
|
667 |
|
|
|
— |
|
Inventories, net |
|
|
10,323 |
|
|
|
5,394 |
|
Income taxes receivable |
|
|
120 |
|
|
|
1,188 |
|
Prepaid expenses and other current assets |
|
|
3,521 |
|
|
|
2,438 |
|
Total current assets |
|
|
70,067 |
|
|
|
101,204 |
|
Property, plant and equipment, net |
|
|
52,628 |
|
|
|
29,810 |
|
Operating right-of-use lease assets |
|
|
18,558 |
|
|
|
— |
|
Goodwill |
|
|
— |
|
|
|
16,613 |
|
Intangible assets, net |
|
|
17,843 |
|
|
|
18,704 |
|
Other non-current assets |
|
|
1,176 |
|
|
|
180 |
|
Total assets |
|
$ |
160,272 |
|
|
$ |
166,511 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
3,485 |
|
|
$ |
2,248 |
|
Accrued liabilities |
|
|
6,590 |
|
|
|
5,495 |
|
Current portion of operating lease liabilities |
|
|
2,253 |
|
|
|
— |
|
Total current liabilities |
|
|
12,328 |
|
|
|
7,743 |
|
Deferred tax liabilities |
|
|
2,028 |
|
|
|
3,153 |
|
Other accrued liabilities |
|
|
212 |
|
|
|
273 |
|
Long-term debt, net |
|
|
16,878 |
|
|
|
11,870 |
|
Deferred rent |
|
|
— |
|
|
|
269 |
|
Long-term operating lease liabilities |
|
|
16,830 |
|
|
|
— |
|
Total liabilities |
|
|
48,276 |
|
|
|
23,308 |
|
Stockholders’ equity: |
|
|
|
|
|
|
||
Preferred stock |
|
|
— |
|
|
|
— |
|
Common stock |
|
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
|
153,708 |
|
|
|
150,741 |
|
Accumulated deficit |
|
|
(41,712 |
) |
|
|
(7,538 |
) |
Total stockholders’ equity |
|
|
111,996 |
|
|
|
143,203 |
|
Total liabilities and stockholders’ equity |
|
$ |
160,272 |
|
|
$ |
166,511 |
|
7
ALPHA TEKNOVA, INC.
Condensed Statements of Cash Flows
(Unaudited)
(In thousands)
|
|
For the Three Months Ended September 30, |
|
|
For the Nine Months Ended September 30, |
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss |
|
$ |
(22,474 |
) |
|
$ |
(3,251 |
) |
|
$ |
(34,174 |
) |
|
$ |
(6,156 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Bad debt expense |
|
|
2 |
|
|
|
4 |
|
|
|
34 |
|
|
|
235 |
|
Inventory reserve |
|
|
186 |
|
|
|
(23 |
) |
|
|
178 |
|
|
|
676 |
|
Depreciation and amortization |
|
|
729 |
|
|
|
748 |
|
|
|
2,272 |
|
|
|
2,100 |
|
Stock-based compensation |
|
|
968 |
|
|
|
442 |
|
|
|
2,689 |
|
|
|
927 |
|
Deferred taxes |
|
|
(374 |
) |
|
|
(893 |
) |
|
|
(1,125 |
) |
|
|
(1,640 |
) |
Amortization of debt financing costs |
|
|
60 |
|
|
|
43 |
|
|
|
159 |
|
|
|
89 |
|
Non-cash lease expense |
|
|
75 |
|
|
|
11 |
|
|
|
256 |
|
|
|
60 |
|
Loss on disposal of property, plant and equipment |
|
|
210 |
|
|
|
— |
|
|
|
210 |
|
|
|
4 |
|
Goodwill impairment |
|
|
16,613 |
|
|
|
|
|
|
16,613 |
|
|
|
— |
|
|
Other |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(10 |
) |
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Accounts receivable |
|
|
227 |
|
|
|
(504 |
) |
|
|
(949 |
) |
|
|
(170 |
) |
Contract assets |
|
|
(667 |
) |
|
|
— |
|
|
|
(667 |
) |
|
|
— |
|
Inventories |
|
|
(2,600 |
) |
|
|
(500 |
) |
|
|
(5,107 |
) |
|
|
(1,497 |
) |
Income taxes receivable |
|
|
(3 |
) |
|
|
447 |
|
|
|
1,068 |
|
|
|
226 |
|
Prepaid expenses and other current assets |
|
|
(1,820 |
) |
|
|
(2,195 |
) |
|
|
(1,083 |
) |
|
|
(1,777 |
) |
Other non-current assets |
|
|
(407 |
) |
|
|
2 |
|
|
|
(996 |
) |
|
|
(5 |
) |
Accounts payable |
|
|
1,247 |
|
|
|
501 |
|
|
|
969 |
|
|
|
468 |
|
Accrued liabilities |
|
|
(283 |
) |
|
|
348 |
|
|
|
343 |
|
|
|
553 |
|
Other |
|
|
(21 |
) |
|
|
(17 |
) |
|
|
(61 |
) |
|
|
(70 |
) |
Cash used in operating activities |
|
|
(8,332 |
) |
|
|
(4,837 |
) |
|
|
(19,371 |
) |
|
|
(5,987 |
) |
Investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Purchase of property, plant and equipment |
|
|
(6,582 |
) |
|
|
(3,907 |
) |
|
|
(23,419 |
) |
|
|
(12,465 |
) |
Proceeds from loan to related party |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
529 |
|
Proceeds on sales of short-term marketable securities |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,132 |
|
Proceeds from maturities of short-term marketable securities |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
695 |
|
Cash used in investing activities |
|
|
(6,582 |
) |
|
|
(3,907 |
) |
|
|
(23,419 |
) |
|
|
(10,109 |
) |
Financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Proceeds from long-term debt |
|
|
— |
|
|
|
1 |
|
|
|
5,135 |
|
|
|
11,890 |
|
Payment of debt issuance costs |
|
|
— |
|
|
|
— |
|
|
|
(151 |
) |
|
|
(153 |
) |
Payment of exit fee costs |
|
|
— |
|
|
|
— |
|
|
|
(135 |
) |
|
|
— |
|
Payment of costs related to initial public offering |
|
|
— |
|
|
|
(1,266 |
) |
|
|
— |
|
|
|
(3,615 |
) |
Proceeds from initial public offering, net of underwriters’ commissions and discounts |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
102,672 |
|
Proceeds from exercise of stock options |
|
|
35 |
|
|
|
— |
|
|
|
134 |
|
|
|
— |
|
Proceeds from issuance of common stock under employee stock purchase plan |
|
|
— |
|
|
|
— |
|
|
|
144 |
|
|
|
— |
|
Cash provided by financing activities |
|
|
35 |
|
|
|
(1,265 |
) |
|
|
5,127 |
|
|
|
110,794 |
|
Change in cash and cash equivalents |
|
|
(14,879 |
) |
|
|
(10,009 |
) |
|
|
(37,663 |
) |
|
|
94,698 |
|
Cash and cash equivalents at beginning of period |
|
|
64,734 |
|
|
|
108,022 |
|
|
|
87,518 |
|
|
|
3,315 |
|
Cash and cash equivalents at end of period |
|
$ |
49,855 |
|
|
$ |
98,013 |
|
|
$ |
49,855 |
|
|
$ |
98,013 |
|
8
ALPHA TEKNOVA, INC.
Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures
(Unaudited)
(In thousands)
|
|
For the Three Months Ended September 30, |
|
|
For the Nine Months Ended September 30, |
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Net loss – as reported |
|
$ |
(22,474 |
) |
|
$ |
(3,251 |
) |
|
$ |
(34,174 |
) |
|
$ |
(6,156 |
) |
Add back: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income (expense), net |
|
|
70 |
|
|
|
(255 |
) |
|
|
85 |
|
|
|
(553 |
) |
Benefit from income taxes |
|
|
(374 |
) |
|
|
(892 |
) |
|
|
(1,128 |
) |
|
|
(1,640 |
) |
Depreciation expense |
|
|
442 |
|
|
|
461 |
|
|
|
1,411 |
|
|
|
1,239 |
|
Amortization of intangible assets |
|
|
287 |
|
|
|
287 |
|
|
|
861 |
|
|
|
861 |
|
EBITDA |
|
$ |
(22,189 |
) |
|
$ |
(3,140 |
) |
|
$ |
(33,115 |
) |
|
$ |
(5,143 |
) |
Other and one-time expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Stock-based compensation expense |
|
|
968 |
|
|
|
442 |
|
|
|
2,689 |
|
|
|
927 |
|
Goodwill impairment charge |
|
|
16,613 |
|
|
|
— |
|
|
|
16,613 |
|
|
|
— |
|
Adjusted EBITDA |
|
$ |
(4,608 |
) |
|
$ |
(2,698 |
) |
|
$ |
(13,813 |
) |
|
$ |
(4,216 |
) |
|
|
For the Three Months Ended September 30, |
|
|
For the Nine Months Ended September 30, |
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Cash used in operating activities |
|
$ |
(8,332 |
) |
|
$ |
(4,837 |
) |
|
$ |
(19,371 |
) |
|
$ |
(5,987 |
) |
Purchase of property, plant and equipment |
|
|
(6,582 |
) |
|
|
(3,907 |
) |
|
|
(23,419 |
) |
|
|
(12,465 |
) |
Free Cash Flow |
|
$ |
(14,914 |
) |
|
$ |
(8,744 |
) |
|
$ |
(42,790 |
) |
|
$ |
(18,452 |
) |
9